Literature DB >> 20011735

The role of iron in the pathophysiology and treatment of chronic hepatitis C.

Leslie Price1, Kris V Kowdley.   

Abstract

Increased hepatic iron content may be observed in patients with chronic hepatitis C infection, and may contribute to disease severity. The presence of hemochromatosis gene mutations is associated with increased hepatic iron accumulation and may lead to accelerated disease progression. Hepatic iron depletion has been postulated to decrease the risk of hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. It is possible that iron depletion stabilizes or improves liver histology and slows disease progression in these individuals. The present article reviews the prevalence and risk factors for hepatic iron overload in chronic hepatitis C, with emphasis on the available data regarding the efficacy of iron depletion in the treatment of this common liver disease.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20011735      PMCID： PMC2805519          DOI： 10.1155/2009/290383

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN： 0835-7900            Impact factor:   3.522


  59 in total

1.  Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis.

Authors:  C Chapoutot; M Esslimani; Z Joomaye; J Ramos; P Perney; C Laurent; P Fabbro-Peray; D Larrey; J Domergue; F Blanc
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

2.  Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial.

Authors:  R J Fontana; J Israel; P LeClair; B F Banner; K Tortorelli; N Grace; R A Levine; G Fiarman; M Thiim; A S Tavill; H L Bonkovsky
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

3.  Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet.

Authors:  J Kato; M Kobune; T Nakamura; G Kuroiwa; K Takada; R Takimoto; Y Sato; K Fujikawa; M Takahashi; T Takayama; T Ikeda; Y Niitsu
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

4.  Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis.

Authors:  F Negro; K Samii; L Rubbia-Brandt; R Quadri; P J Male; J P Zarski; M Baud; E Giostra; P Beris; A Hadengue
Journal:  J Med Virol       Date:  2000-01       Impact factor: 2.327

5.  Beneficial influence of an indigenous low-iron diet on serum indicators of iron status in patients with chronic liver disease.

Authors:  N Tandon; V Thakur; R K Guptan; S K Sarin
Journal:  Br J Nutr       Date:  2000-03       Impact factor: 3.718

6.  C282Y mutation and hepatic iron status in hepatitis C and cryptogenic cirrhosis.

Authors:  P Lal; H Fernandes; B Koneru; E Albanese; M Hameed
Journal:  Arch Pathol Lab Med       Date:  2000-11       Impact factor: 5.534

7.  Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial.

Authors:  A M Di Bisceglie; H L Bonkovsky; S Chopra; S Flamm; R K Reddy; N Grace; P Killenberg; C Hunt; C Tamburro; A S Tavill; R Ferguson; E Krawitt; B Banner; B R Bacon
Journal:  Hepatology       Date:  2000-07       Impact factor: 17.425

8.  Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations.

Authors:  M Pirisi; C A Scott; C Avellini; P Toniutto; C Fabris; G Soardo; C A Beltrami; E Bartoli
Journal:  Am J Clin Pathol       Date:  2000-04       Impact factor: 2.493

9.  Heterozygosity for the hemochromatosis gene in liver diseases--prevalence and effects on liver histology.

Authors:  T Höhler; S Leininger; H H Köhler; P Schirmacher; P R Galle
Journal:  Liver       Date:  2000-12

10.  Hepatic stellate cells in hepatitis C patients: relationship with liver iron deposits and severity of liver disease.

Authors:  Ana L C Martinelli; Leandra N Z Ramalho; Sergio Zucoloto
Journal:  J Gastroenterol Hepatol       Date:  2004-01       Impact factor: 4.029
View more
  21 in total

1.  Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease.

Authors:  James E Nelson; Laura Wilson; Elizabeth M Brunt; Matthew M Yeh; David E Kleiner; Aynur Unalp-Arida; Kris V Kowdley
Journal:  Hepatology       Date:  2010-11-29       Impact factor: 17.425

2.  Iron Overload in Patients With Chronic Liver Disease.

Authors:  Kris V Kowdley
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-11

Review 3.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

4.  Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.

Authors:  Motoyuki Kohjima; Tsuyoshi Yoshimoto; Munechika Enjoji; Nobuyoshi Fukushima; Kunitaka Fukuizumi; Tsukasa Nakamura; Miho Kurokawa; Nao Fujimori; Yusuke Sasaki; Yasushi Shimonaka; Yusuke Murata; Susumu Koyama; Ken Kawabe; Kazuhiro Haraguchi; Yorinobu Sumida; Naohiko Harada; Masaki Kato; Kazuhiro Kotoh; Makoto Nakamuta
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

Review 5.  Hepatitis C, porphyria cutanea tarda and liver iron: an update.

Authors:  F Ryan Caballes; Hossein Sendi; Herbert L Bonkovsky
Journal:  Liver Int       Date:  2012-04-17       Impact factor: 5.828

6.  Transforming a clinical fluorescent dye to sense and treat iron overload disorders: a new reverse translational approach in precision medicine.

Authors:  Junqing Wang; Gang Liu; Yì Xiáng J Wáng
Journal:  Quant Imaging Med Surg       Date:  2022-05

7.  Gender difference of alanine aminotransferase elevation may be associated with higher hemoglobin levels among male adolescents.

Authors:  Solomon Chih-Cheng Chen; Jun-Jun Yeh; Mei-Hwei Chang; Yu-Kuei Liao; Li-Chen Hsiao; Choo-Aun Neoh; Teck-Siang Tok; Jung-Der Wang
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

Review 8.  Mechanistic and regulatory aspects of intestinal iron absorption.

Authors:  Sukru Gulec; Gregory J Anderson; James F Collins
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-07-03       Impact factor: 4.052

Review 9.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

Review 10.  Co-infections as Modulators of Disease Outcome: Minor Players or Major Players?

Authors:  Priti Devi; Azka Khan; Partha Chattopadhyay; Priyanka Mehta; Shweta Sahni; Sachin Sharma; Rajesh Pandey
Journal:  Front Microbiol       Date:  2021-07-06       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.